Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Shares Outstanding (Weighted Average) (2016 - 2025)

ProQR Therapeutics' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $5.0 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 94.55% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 94.55% decrease, with the full-year FY2025 number at $5.0 million, down 94.55% from a year prior.
  • Shares Outstanding (Weighted Average) hit $5.0 million in Q4 2025 for ProQR Therapeutics, up from $374.1 in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for PRQR hit a ceiling of $92.0 million in Q4 2024 and a floor of $97.77 in Q1 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $17.1 million across 5 years, with a median of $339.45 in 2023.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 69.8% in 2025, down 94.55% in 2025.
  • Tracing PRQR's Shares Outstanding (Weighted Average) over 5 years: stood at $85.6 million in 2021, then fell by 14.66% to $73.1 million in 2022, then rose by 19.25% to $87.2 million in 2023, then increased by 5.54% to $92.0 million in 2024, then plummeted by 94.55% to $5.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PRQR at $5.0 million in Q4 2025, $374.1 in Q3 2025, and $237.71 in Q2 2025.